Yahoo
NasdaqGS - Nasdaq Real Time Price USD

Amphastar Pharmaceuticals, Inc. (AMPH)

28.66 +1.00 (+3.62%)
As of 1:39:02 PM EST. Market Open.
Trade AMPH on Coinbase
AMPH Q3 2026 earnings call
Replay the call for the latest insights.
Read transcript
Chart Range Bar
Loading chart for AMPH
  • Previous Close 27.66
  • Open 29.44
  • Bid 22.10 x 200
  • Ask 35.82 x 200
  • Day's Range 27.84 - 30.79
  • 52 Week Range 16.65 - 30.79
  • Volume 405,875
  • Avg. Volume 474,196
  • Market Cap (intraday) 1.219B
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) 16.91
  • EPS (TTM) 1.69
  • Earnings Date Nov 5, 2026
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 22.50
  • Zacks Rating Bearish

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Glucagon for injection emergency kit; Enoxaparin, an injectable form of low molecular weight heparin for the prevention and treatment of deep vein thrombosis; and REXTOVY and Naloxone for opioid overdose. The company also provides Cortrosyn, a lyophilized power for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency; Amphadase, a bovine-sourced hyaluronidase injection; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; and emergency syringe products, including atropine, calcium chloride, dextrose, epinephrine, lidocaine, and sodium bicarbonate. In addition, it offers Albuterol sulfate inhalation aerosol for the treatment or prevention of bronchospasm; Iron sucrose injection, an iron replacement product for the treatment of iron deficiency anemia in patients with chronic kidney disease; Teriparatide injection for managing daily osteoporosis therapy; and Ipratropium Bromide HFA inhalation aerosol, an anticholinergic indicated for the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease. Further, the company provides active pharmaceutical ingredient (API) products, such as Recombinant Human Insulin and porcine insulin API. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

www.amphastar.com

1,976

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 11/6/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

AMPH
6.68%
S&P 500 (^GSPC)
8.04%

1-Year Return

AMPH
17.91%
S&P 500 (^GSPC)
10.05%

3-Year Return

AMPH
38.99%
S&P 500 (^GSPC)
69.39%

5-Year Return

AMPH
42.28%
S&P 500 (^GSPC)
57.44%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q3 FY26
Revenue 207.61M
Earnings 37.76M
Profit Margin 18.19%

Q4

FY25

Q1

FY26

Q2

FY26

Q3

FY26

0
50M
100M
150M
200M
5.0%
10.0%
15.0%

Analyst Insights

View More

Analyst Price Targets

20.00 Low
22.50 Average
28.66 Current
30.00

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 11/6/2026
Analyst Wells Fargo
Rating Action Maintains
Rating Equal-Weight
Price Action Raises
Price Target 20 -> 25

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    13.27%

  • Return on Assets (ttm)

    6.03%

  • Return on Equity (ttm)

    12.44%

  • Revenue (ttm)

    745.79M

  • Net Income Avi to Common (ttm)

    98.96M

  • Diluted EPS (ttm)

    1.69

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    230.63M

  • Total Debt/Equity (mrq)

    84.92%

  • Levered Free Cash Flow (ttm)

    14.03M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: